From Nasdaq MarketSite: 2025-04-01 19:09:00

Investors were wary of the pharmaceutical industry due to looming tariffs from the Trump administration, causing major stocks like Pfizer, Merck, and Eli Lilly to drop in price. Despite this, Pfizer’s Abrysvo vaccine received expanded approval in the EU, while Eli Lilly’s tirzepatide found a new distribution outlet. Uncertainty remains regarding the tariffs, but there is hope for a softer approach. Analysts also suggest investing in “Double Down” stock recommendations for potentially lucrative opportunities. The market may have overlooked positive developments amidst the tariff concerns, but flexibility from the Trump team could lead to a more favorable outcome for the pharma sector.



Read more at Nasdaq MarketSite: Why Major Pharmaceutical Stocks Tumbled on Tuesday